Efficacy and Safety of Benbromarne and Allopurinol for Primary Gout ULT: A Meta-Analysis_Chinese Journal of Evidence-Based Medicine

Authors：

 SHAO Li , WEI Li

Department of Rheumatism, Medical College, Xinjiang University, Urumqi 830054, China;

Corresponding author：

SHAO Li, Email: wlfengshike@163.com

Keywords：

Benzbromarone; Allopurinol; Primary gout; Hyperuricemic urate-lowering therapy (ULT); Randomized controlled trial; Systematic review; Meta-analysis

DOI：

10.7507/1672-2531.20120117

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To compare the efficacy and safety of benzbromarone vs. allopurinol for primary gout.
Methods Searching PubMed, Cochrane Library, EMbase, CNKI, VIP and CBM, randomized controlled trials were collected and the quality of RCTs was evaluated using Cochrane systematic review. Meta-analysis was performed.
Results 6 RCTs were included in this study,with a total of 350 patients. Meta-analysis showed that there was no statistical significance in total effective rate between two groups (P gt;0.05). 4 RCTs were enrolled in comparison of ADR. There was statistical significance between two groups (P lt;0.05).
Conclusion There is no significant difference in the efficacy between benzbromarone and allopurinol for the primary gout.But benzbromarone is safe than allopurinol for primary gout .

Citation： SHAO Li,WEI Li. Efficacy and Safety of Benbromarne and Allopurinol for Primary Gout ULT: A Meta-Analysis. Chinese Journal of Evidence-Based Medicine, 2012, 12(6): 722-726. doi: 10.7507/1672-2531.20120117 Copy

1.	郭义恒, 于改革. 氟伐他汀治疗高尿酸血症肾病的Ⅰ期临床观察. 实用杂志, 2008, 22(4): 295-296.
2.	党群, 王敬, 张莹. 高尿酸血症与高血压发生心血管事件的相关性探讨. 中华实用诊断与治疗杂志, 2006, 20(7): 505-506.
3.	贾强, 娄姗姗, 孟召, 等. 性别和年龄与高尿酸血症及代谢综合征的关系. 中国全科医师, 2011, 10(8): 567-568.
4.	李加平, 喻巧云. 高尿酸血症与代谢综合征的相关性研究. 国际检验医学杂志, 2011, 32(12): 1322-1325.
5.	张秀娟, 辛长贵. 原发性高尿血症及痛风易感基因研究进展. 中华内分泌代谢杂志, 2011, 27(7): 611-612.
6.	Masbernard A, Giudicelli CP. Ten years’ experience with benzbromarone in the management of gout and hyperuricaemia. S Afr Med, 1981, 59(65): 701-706.
7.	van der Klauw MM, Houtman PM, Stricker BH, et al. Hepatic injury caused by benzbromarone. J Hepatol, 1994, 20(3): 376-379.
8.	Wagayama H, Shiraki K, Sugimoto K, et al. Fatal fulminant hepatic failure associated with benzbromarone. J Hepatol, 2000, 32(5): 874.
9.	Suzuki T, Suzuki T, Kimura M, et al. A case of fulminant hepatitis, possibly caused by benzbromarone. Nippon Shokakibyo Gakkai Zasshi, 2001, 98(4): 421-425.
10.	叶任高, 陆再英. 内科学(第6版). 北京: 人民卫生出版社, 2006: 862.
11.	Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration, 2008.
12.	胡政国, 刘家铎. 苯溴马隆与别嘌呤醇治疗高尿酸血症的疗效比较. 中国基层医药, 2010, 17(18): 2506-2507.
13.	王雪君, 沈建军. 小剂量苯溴马隆与别嘌呤醇治疗高尿酸血60例疗效观察. 中国现代应用药学杂志, 2007, 24(4): 337-338.
14.	赵占正, 肖静, 刘章锁. 苯溴马隆与别嘌呤醇治疗高尿酸血症/痛风的疗效观察. 中国误诊学杂志, 2005, 5(2): 281-282.
15.	韩文娟, 钱培玲, 顾咏亮, 等. 苯溴马隆与别嘌醇治疗高尿酸血症临床效果对照. 上海医药, 2004, 25(10): 468-469.
16.	Reinders MK, Haagsma C, Jansen TL, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis, 2009, 68(6): 892-897.
17.	Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis, 1998, 57(9): 545-549.

1. 郭义恒, 于改革. 氟伐他汀治疗高尿酸血症肾病的Ⅰ期临床观察. 实用杂志, 2008, 22(4): 295-296.
2. 党群, 王敬, 张莹. 高尿酸血症与高血压发生心血管事件的相关性探讨. 中华实用诊断与治疗杂志, 2006, 20(7): 505-506.
3. 贾强, 娄姗姗, 孟召, 等. 性别和年龄与高尿酸血症及代谢综合征的关系. 中国全科医师, 2011, 10(8): 567-568.
4. 李加平, 喻巧云. 高尿酸血症与代谢综合征的相关性研究. 国际检验医学杂志, 2011, 32(12): 1322-1325.
5. 张秀娟, 辛长贵. 原发性高尿血症及痛风易感基因研究进展. 中华内分泌代谢杂志, 2011, 27(7): 611-612.
6. Masbernard A, Giudicelli CP. Ten years’ experience with benzbromarone in the management of gout and hyperuricaemia. S Afr Med, 1981, 59(65): 701-706.
7. van der Klauw MM, Houtman PM, Stricker BH, et al. Hepatic injury caused by benzbromarone. J Hepatol, 1994, 20(3): 376-379.
8. Wagayama H, Shiraki K, Sugimoto K, et al. Fatal fulminant hepatic failure associated with benzbromarone. J Hepatol, 2000, 32(5): 874.
9. Suzuki T, Suzuki T, Kimura M, et al. A case of fulminant hepatitis, possibly caused by benzbromarone. Nippon Shokakibyo Gakkai Zasshi, 2001, 98(4): 421-425.
10. 叶任高, 陆再英. 内科学(第6版). 北京: 人民卫生出版社, 2006: 862.
11. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration, 2008.
12. 胡政国, 刘家铎. 苯溴马隆与别嘌呤醇治疗高尿酸血症的疗效比较. 中国基层医药, 2010, 17(18): 2506-2507.
13. 王雪君, 沈建军. 小剂量苯溴马隆与别嘌呤醇治疗高尿酸血60例疗效观察. 中国现代应用药学杂志, 2007, 24(4): 337-338.
14. 赵占正, 肖静, 刘章锁. 苯溴马隆与别嘌呤醇治疗高尿酸血症/痛风的疗效观察. 中国误诊学杂志, 2005, 5(2): 281-282.
15. 韩文娟, 钱培玲, 顾咏亮, 等. 苯溴马隆与别嘌醇治疗高尿酸血症临床效果对照. 上海医药, 2004, 25(10): 468-469.
16. Reinders MK, Haagsma C, Jansen TL, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis, 2009, 68(6): 892-897.
17. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis, 1998, 57(9): 545-549.

Previous Article
Digestive Enzyme for Dyspepsia: A Systematic Review
Next Article
Gabapentin for Restless Legs Syndrome: A Systematic Review

Chinese Journal of Evidence-Based Medicine

Efficacy and Safety of Benbromarne and Allopurinol for Primary Gout ULT: A Meta-Analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content